腹腔热灌注化疗联合静脉化疗与单纯静脉化疗治疗腹腔转移癌的自身对照研究

目的:对比腹腔热灌注化疗联合静脉化疗与单纯静脉化疗治疗腹腔转移癌的不良反应以及疗效。方法:采用自身对照方法,选取56例序贯进行腹腔热灌注化疗联合静脉化疗和单纯静脉化疗患者,分别观察腹腔热灌注化疗联合静脉化疗和单纯静脉化疗的毒副反应并对比,同时随访生存情况。结果:腹腔热灌注化疗联合静脉化疗与单纯静脉化疗相比,腹痛发生率较高(25%与8.9%),Ⅲ+Ⅳ白细胞减少较低(16.%与21%),而胃肠道反应比较,差异无统计学意义(P>0.05),中位总生存期为22个月。结论:对比单纯静脉化疗,腹腔热灌注化疗联合静脉化疗治疗腹腔转移癌安全有效,但腹痛发生率较高。

Self- controlled study of intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy versus intravenous chemotherapy in patients with peritoneal carcinomatosis

Objective To compare efficacy and side effect of intraperitoneal hyperthermic perfusion chemotherapy combined with intra-venous chemotherapy versus intravenous chemotherapy in patients with peritoneal carcinomatosis. Method Fifty six patients were selected on self-control design principle. intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy or intrave-nous chemotherapy were conducted sequential. Efficacy and Side Effect were observed and survival were followed. Results Contrast to intra-venous chemotherapy,intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy was safe. the ratio of abdominal pain was higher and the ratio of grade Ⅲ - Ⅳ leucopenia was lower. the meidian survival time was 22 months. Conclusion Contrast to intravenous chemotherapy,intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy is safe and effective in patients with peritoneal carcinomatosis. but the ratio of abdominal pain is higher.